Stockscreener 앱 받기
178.59
0.24%
0.64
전일 마감가:
$177.95
열려 있는:
$178.01
하루 거래량:
363.85K
Relative Volume:
0.29
시가총액:
$19.72B
수익:
$9.54B
순이익/손실:
$841.00M
주가수익비율:
24.00
EPS:
7.44
순현금흐름:
$1.02B
1주 성능:
+0.96%
1개월 성능:
+8.65%
6개월 성능:
+15.75%
1년 성능:
+29.84%
1일 변동 폭
$176.87
$179.28
1주일 범위
$174.32
$179.32
52주 변동 폭
$135.35
$179.32
퀘스트 다이아그노스틱스 Stock (DGX) Company Profile
명칭
Quest Diagnostics Inc
전화
(973) 520-2700
주소
500 PLAZA DRIVE, SECAUCUS
DGX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DGX
Quest Diagnostics Inc
|
178.32 | 19.72B | 9.54B | 841.00M | 1.02B | 7.44 |
|
TMO
Thermo Fisher Scientific Inc
|
422.94 | 159.05B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
199.08 | 140.21B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
478.10 | 35.17B | 3.90B | 887.87M | 798.08M | 10.67 |
|
A
Agilent Technologies Inc
|
108.99 | 30.47B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
153.77 | 26.47B | 15.41B | 1.37B | 2.11B | 7.50 |
퀘스트 다이아그노스틱스 Stock (DGX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-02 | 개시 | Redburn Atlantic | Buy |
| 2025-03-04 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2025-01-06 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-12-17 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | 재개 | Jefferies | Buy |
| 2024-10-23 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2024-08-28 | 재개 | Evercore ISI | In-line |
| 2024-07-10 | 업그레이드 | Citigroup | Neutral → Buy |
| 2024-02-26 | 개시 | Leerink Partners | Market Perform |
| 2024-02-07 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-01-03 | 개시 | Barclays | Equal Weight |
| 2023-12-12 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-06-29 | 개시 | Piper Sandler | Neutral |
| 2023-05-02 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-04-03 | 업그레이드 | Citigroup | Sell → Neutral |
| 2023-01-23 | 개시 | Evercore ISI | In-line |
| 2022-11-17 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2022-08-22 | 재개 | Morgan Stanley | Equal-Weight |
| 2022-04-04 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-02-23 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-02-02 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-01-28 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2021-05-04 | 업그레이드 | UBS | Neutral → Buy |
| 2021-03-12 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-10-21 | 업그레이드 | Argus | Hold → Buy |
| 2020-07-29 | 업그레이드 | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2020-07-14 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2020-06-09 | 업그레이드 | Wells Fargo | Underweight → Equal Weight |
| 2020-06-02 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2020-04-28 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-04-27 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-04-27 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2020-03-27 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-01-08 | 개시 | Wells Fargo | Underweight |
| 2020-01-07 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2019-12-19 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
| 2019-07-15 | 다운그레이드 | Goldman | Neutral → Sell |
| 2019-04-02 | 업그레이드 | Jefferies | Hold → Buy |
| 2019-03-18 | 재개 | Credit Suisse | Neutral |
| 2019-01-31 | 다운그레이드 | Argus | Buy → Hold |
| 2019-01-17 | 개시 | UBS | Neutral |
| 2019-01-03 | 다운그레이드 | BofA/Merrill | Neutral → Underperform |
| 2018-12-03 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2018-11-30 | 다운그레이드 | Goldman | Buy → Neutral |
모두보기
퀘스트 다이아그노스틱스 주식(DGX)의 최신 뉴스
Take the Zacks Approach to Beat the Markets: ADMA Biologics, Limbach, Quest Diagnostics in Focus - TradingView
Quest Diagnostics Stock: A Leader But Waiting For Better Price (NYSE:DGX) - Seeking Alpha
Quest Settles Fired Black Phlebotomist's Retaliation Suit - Law360
Fitch elevates Quest Diagnostics’ rating to ’BBB+’ with stable outlook By Investing.com - Investing.com Canada
Fitch elevates Quest Diagnostics’ rating to ’BBB+’ with stable outlook - Investing.com
Piper Sandler Adjusts Price Target on Quest Diagnostics to $200 From $180, Maintains Neutral Rating - marketscreener.com
Decoding Quest Diagnostics Inc (DGX): A Strategic SWOT Insight - GuruFocus
Here's How Much You Would Have Made Owning Quest Diagnostics Stock In The Last 5 Years - Benzinga
Truist Financial Keeps Their Hold Rating on Quest Diagnostics (DGX) - The Globe and Mail
These Analysts Boost Their Forecasts On Quest Diagnostics After Better-Than-Expected Q1 Earnings - Benzinga
Morgan Stanley Adjusts Quest Diagnostics Price Target to $182 From $172, Maintains Overweight Rating - marketscreener.com
Baird Adjusts Quest Diagnostics Price Target to $194 From $191, Maintains Outperform Rating - marketscreener.com
Jefferies Adjusts Quest Diagnostics Price Target to $195 From $190, Maintains Buy Rating - marketscreener.com
Quest Diagnostics (DGX) Sees Price Target Increase Following Str - GuruFocus
Mizuho Securities Adjusts Quest Diagnostics Price Target to $190 From $189 - marketscreener.com
Quest Diagnostics (DGX) Sees Price Target Increase Following Strong Q1 Results | DGX Stock News - GuruFocus
A Glimpse Into The Expert Outlook On Quest Diagnostics Through 12 Analysts - Benzinga
Quest Diagnostics Incorporated (NYSE:DGX) Q1 2025 Earnings Call Transcript - Insider Monkey
Truist Raises Price Target on Quest Diagnostics to $190 From $182, Keeps Hold Rating - marketscreener.com
Quest Diagnostics (DGX) Sees Price Target Boost from Barclays | - GuruFocus
Quest Diagnostics (DGX) Sees Price Target Boost from Barclays | DGX Stock News - GuruFocus
Quest Diagnostics (DGX) Stock Analysis: Unpacking the 5.32% Potential Upside for Investors - DirectorsTalk Interviews
Quest Diagnostics Inc (DGX) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
Quest Diagnostics Inc (DGX) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Innovations - GuruFocus
Quest Diagnostics: Q1 Earnings Snapshot - CTPost
Quest Diagnostics earnings bolstered by March rebound, sending stock up 3% - MSN
Barclays Raises Quest Diagnostics' Price Target to $185 From $175 - marketscreener.com
Evercore ISI Adjusts Quest Diagnostics Price Target to $180 From $175 - marketscreener.com
Quest Diagnostics Inc (DGX) Trading 6.97% Higher on Apr 22 - GuruFocus
Quest Diagnostics (DGX) Reports Strong Q1 2025 Revenue Growth - GuruFocus
Leerink Adjusts Price Target on Quest Diagnostics to $189 From $184 - marketscreener.com
Quest Diagnostics Revenue Rebound, Strategic Moves Fuel Outlook ConfidenceQuest Diagnostics (NYSE:DGX) - Benzinga
Quest Diagnostics (DGX) Increases EPS Outlook After Strong Q1 Performance - GuruFocus
Quest Diagnostics Q1 Earnings & Revenues Top Estimates, Stock Up - Nasdaq
Quest Diagnostics up 8% following earnings beats, EPS guidance raise - Seeking Alpha
Quest Diagnostics Posts Better-Than-Expected Earnings, Joins Pentair, 3M, Danaher And Other Big Stocks Moving Higher On TuesdayAkso Health (NASDAQ:AHG), Bitdeer Technologies (NASDAQ:BTDR) - Benzinga
Quest Diagnostics Shines With Strong Profits And Revenue Growth - Finimize
Quest Diagnostics Reports First Quarter 2025 Financial Results; Reaffirms Revenue and Adjusted Diluted EPS Guidance for Full Year 2025 - The Malaysian Reserve
Quest Diagnostics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Quest Diagnostics’ Q1 Earnings Align With Wall Street Estimates: Retail’s In Wait-And-Watch Mode - MSN
Quest Diagnostics (DGX) Q1 Earnings and Revenues Beat Estimates - Yahoo
Quest beats quarterly profit estimates on strong demand for diagnostic tests - marketscreener.com
Strong Q1 Revenue Performance by Quest Diagnostics (DGX) Exceeds Projections | DGX Stock News - GuruFocus
Quest Diagnostics Inc (DGX) Q1 2025 Earnings: EPS of $1.94 Beats Estimate, Revenue Hits $2.65 Billion - GuruFocus
Quest Diagnostics Q1 Adjusted Earnings, Revenue Increase; 2025 Adjusted Earnings Outlook Affirmed - marketscreener.com
Quest Diagnostics (DGX) Beats Q1 Estimates, Adjusts FY25 Guidance - GuruFocus
Quest Diagnostics Reports First Quarter 2025 Financial Results - TradingView
Quest (NYSE:DGX) Beats Q1 Sales Targets - Yahoo Finance
Quest Diagnostics Incorporated Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Quest Diagnostics Reports First Quarter 2025 Financial Results; Reaffirms Revenue and Adjusted Diluted EPS Guidance for Full Year 2025 – Company AnnouncementFT.com - Financial Times
Pcos Diagnostic Market Detailed In New Research Report 2025 | - openPR.com
퀘스트 다이아그노스틱스 (DGX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.15%
0.59%
자본화:
|
볼륨(24시간):